Clinical trials: Uncontrolled Asthma
Asthma; Eosinophilic
Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma
The purpose of this phase III Study is to demonstrate the efficacy of at least one dose of CHF 6532 on moderate and severe asthma exacerbations rate compared to placebo.
- Trial name
- PERSEA (NCT04049175)
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Bulgaria
- Volunteers
- 810 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma
The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-38518168 compared with placebo in participants with persistent asthma that is inadequately…
- Trial name
- NCT01823016
- Testing
- JNJ-38518168
- Where
- 54 sites in United States, Canada and 4 more
- Volunteers
- 166 people
- Sponsor
- Janssen Research & Development, LLC
Asthma
Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma
A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma
- Trial name
- NAVIGATOR (NCT03347279)
- Testing
- Experimental: Tezepelumab
- Where
- 289 sites in United States, Argentina and 16 more
- Volunteers
- 1,061 people
- Sponsor
- AstraZeneca
Asthma
Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy
This observational study aims to collect data in clinical practice on the clinical profile of patients treated with Tezepelumab from Q1 2024 to Q1 2025 according to the approved and reimbursed indication in Italy
- Trial name
- FRONTEDGE (NCT06948396)
- Testing
- Tezepelumab
- Where
- 28 sites in Italy
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
Severe Asthma
Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium
This study aims to assess health and quality of life outcomes in patients treated with benralizumab, within a Belgian Real-World setting.
- Trial name
- BE-REAL (NCT04221802)
- Where
- 10 sites in Belgium
- Volunteers
- 76 people
- Sponsor
- AstraZeneca
Asthma
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
This is a Phase IIb, randomized, placebo-controlled, double-blind, multicenter, multi-arm study which will evaluate efficacy, safety, and pharmacokinetic of MSTT1041A compared with placebo as add-on therapy in participants with…
- Trial name
- NCT02918019
- Testing
- MSTT1041A
- Where
- 138 sites in United States, Argentina and 13 more
- Volunteers
- 517 people
- Sponsor
- Hoffmann-La Roche
Asthma
Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists
This is a study comparing CHF 5993 pMDI HFA-152a with CHF 1535 pMDI HFA-134a in Chinese patients with asthma uncontrolled on medium doses of ICS+LABA.
- Trial name
- TRICHECO (NCT07546981)
- Testing
- Experimental: Participant Group CHF 5993 pMDI HFA-152a, Active Comparator: CHF 1535 100/6 μg pMDI HFA-134a
- Where
- 2 sites in China
- Volunteers
- 554 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma
Study D9181C00001 is a Phase II, randomised, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of MEDI3506 in adult participants…
- Trial name
- FRONTIER-3 (NCT04570657)
- Testing
- MEDI3506
- Where
- 65 sites in United States, Argentina and 5 more
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Asthma
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week…
- Trial name
- AJAX (NCT06020014)
- Testing
- AZD4604
- Where
- 124 sites in United States, Argentina and 16 more
- Volunteers
- 339 people
- Sponsor
- AstraZeneca
Uncontrolled Asthma
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled…
- Trial name
- STRATOS2 (NCT02194699)
- Testing
- Experimental: Tralokinumab
- Where
- 234 sites in United States, Canada and 11 more
- Volunteers
- 856 people
- Sponsor
- AstraZeneca
Asthma
Evaluation of Dupilumab in Children With Uncontrolled Asthma
Primary Objective: To evaluate the efficacy of dupilumab in children 6 to less than (<) 12 years of age with uncontrolled persistent asthma.
- Trial name
- VOYAGE (NCT02948959)
- Testing
- Dupilumab, Asthma Controller Therapies, Asthma Reliever Therapies
- Where
- 99 sites in United States, Argentina and 16 more
- Volunteers
- 408 people
- Sponsor
- Sanofi
Asthma
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled…
- Trial name
- FLASH (NCT05251259)
- Testing
- Atuliflapon
- Where
- 234 sites in United States, Argentina and 18 more
- Volunteers
- 670 people
- Sponsor
- AstraZeneca
Asthma
Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma
The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-39758979 compared with placebo in patients with uncontrolled asthma despite current treatment with inhaled corticosteroids and/or long-acting…
- Trial name
- NCT01493882
- Testing
- JNJ-39758979 30 mg/d, JNJ-39758979 100 mg/d, JNJ-39758979 300 mg/d
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pulmonary Disease, Chronic Obstructive
A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma
This study is a multi-centre, randomised, double-blind, placebo-controlled (with rescue medication), two period crossover study in subjects with persistent uncontrolled asthma, currently not treated with an inhaled corticosteroid…
- Trial name
- NCT02567708
- Testing
- GSK2269557 DPI
- Where
- 12 sites in Germany
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Asthma
TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA
Evaluate the superiority of CHF 5993 100/6/12.5 µg Pressurised Metered Dose Inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate (BDP) plus formoterol fumarate (FF) plus glycopyrronium bromide [GB]) versus…
- Trial name
- TRIMARAN (NCT02676076)
- Testing
- CHF 5993 100/6/12.5, CHF 1535 100/6 µg
- Where
- Germany
- Volunteers
- 1,155 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils…
- Trial name
- NCT02452190
- Testing
- Reslizumab
- Where
- 226 sites in United States, Argentina and 19 more
- Volunteers
- 468 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma
Subjects who completed either D5180C00007 or D5180C00009 will be offered the opportunity to consent for the Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate…
- Trial name
- DESTINATION (NCT03706079)
- Testing
- Tezepelumab
- Where
- 180 sites in United States, Argentina and 16 more
- Volunteers
- 951 people
- Sponsor
- AstraZeneca